Who will be my future patients? What are the signals of a patient ready for my product? Who will likely be compliant and stay on therapy? Who will not? Why will Rxs not get converted to starts? Why will patients discontinue? These questions are all fair game but they require varying degrees of patient longitudinal integrity.
In the early days of specialty pharmacy drugs each specialty pharmacy would de-identify their own data before sending it to the manufacturer. This approach allows a manufacturer to understand the flow of prescriptions through the specialty pharmacies (i.e. fill rate and time to fill performance) or the sales by prescriber, but it gave a distorted view of adherence and persistency. In the past 5 to 6 years specialty pharmacy drugs increasingly use a single data aggregator to de-identify PHI across all of the specialty pharmacies that provide data, which creates a longitudinal patient view across all of the pharmacies. This approach enables a meaningful view of adherence and persistency. But there are still important questions that these two data strategies don’t address.
It is possible to extend the longitudinal patient view beyond the network of specialty pharmacies and patient support providers, so that visibility to the de-identified patient includes other sites of dispensing/administration, the complete journey before and after use of my drug, and even visibility to comorbidities and other care/treatments. This is possible by applying the PHI de-identification used for pharmacy and medical claims to the specialty pharmacy data. This approach creates a longitudinal view of patients across the market and expands the universe of business questions that can be answered.
Consider that a longitudinal market view of patients includes attributes about the patient, physician and payer. These attributes enable granular segmentation and modeling, which is the starting point for finding meaningful insights and then impactful actions. This is how I can identify the granular segments that will be my future patients and the signals for the future starts/switches. This is how I can understand my patients better than they know themselves.